Mark S. Diamond

4.4k total citations · 2 hit papers
13 papers, 3.5k citations indexed

About

Mark S. Diamond is a scholar working on Oncology, Immunology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Mark S. Diamond has authored 13 papers receiving a total of 3.5k indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Oncology, 9 papers in Immunology and 3 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Mark S. Diamond's work include Immunotherapy and Immune Responses (7 papers), Cancer Immunotherapy and Biomarkers (5 papers) and Immune Cell Function and Interaction (4 papers). Mark S. Diamond is often cited by papers focused on Immunotherapy and Immune Responses (7 papers), Cancer Immunotherapy and Biomarkers (5 papers) and Immune Cell Function and Interaction (4 papers). Mark S. Diamond collaborates with scholars based in United States, Australia and Germany. Mark S. Diamond's co-authors include Robert D. Schreiber, Kenneth M. Murphy, Hirokazu Matsushita, J. Michael White, Gavin P. Dunn, Brian T. Edelson, Emil R. Unanue, Kai Hildner, Theresa L. Murphy and Whitney E. Purtha and has published in prestigious journals such as Science, Proceedings of the National Academy of Sciences and Nature Communications.

In The Last Decade

Mark S. Diamond

13 papers receiving 3.5k citations

Hit Papers

Batf3 Deficiency Reveals a Critical Role for CD8α + Dendr... 2008 2026 2014 2020 2008 2011 500 1000 1.5k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Batf3 Deficiency Reveals a Critical Role for CD8α + Dendritic Cells in Cytotoxic T Cell Immunity
    2008 1.5k citations Kai Hildner, Brian T. Edelson et al. Science profile →
  2. Type I interferon is selectively required by dendritic cells for immune rejection of tumors
    2011 864 citations Mark S. Diamond, Michelle Kinder et al. The Journal of Experimental Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Mark S. Diamond United States 9 2.9k 1.4k 718 298 224 13 3.5k
Helen Sabzevari United States 27 2.3k 0.8× 1.7k 1.2× 689 1.0× 180 0.6× 221 1.0× 55 3.4k
Surojit Sarkar United States 23 2.9k 1.0× 1.0k 0.7× 545 0.8× 258 0.9× 480 2.1× 47 3.7k
Daniel T. Utzschneider Switzerland 19 2.3k 0.8× 1.6k 1.1× 605 0.8× 133 0.4× 306 1.4× 23 3.1k
Mercedes B. Fuertes Argentina 25 3.5k 1.2× 1.7k 1.2× 1.2k 1.6× 479 1.6× 239 1.1× 38 4.1k
Shahram Salek‐Ardakani United States 37 2.8k 0.9× 1.1k 0.8× 848 1.2× 185 0.6× 463 2.1× 70 3.9k
Laura M. McLane United States 12 1.7k 0.6× 1.1k 0.8× 649 0.9× 175 0.6× 258 1.2× 13 2.6k
Silvia A. Fuertes Marraco Switzerland 17 2.0k 0.7× 1.5k 1.1× 455 0.6× 201 0.7× 295 1.3× 28 2.8k
Shawn D. Blackburn United States 12 2.7k 0.9× 1.5k 1.1× 377 0.5× 250 0.8× 562 2.5× 12 3.4k
Christine Sedlik France 26 1.8k 0.6× 571 0.4× 660 0.9× 238 0.8× 240 1.1× 46 2.5k
Kristen J. Radford Australia 29 2.2k 0.8× 800 0.6× 837 1.2× 113 0.4× 250 1.1× 67 2.9k

Countries citing papers authored by Mark S. Diamond

Since Specialization
Citations

This map shows the geographic impact of Mark S. Diamond's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark S. Diamond with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark S. Diamond more than expected).

Fields of papers citing papers by Mark S. Diamond

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark S. Diamond. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark S. Diamond. The network helps show where Mark S. Diamond may publish in the future.

Co-authorship network of co-authors of Mark S. Diamond

This figure shows the co-authorship network connecting the top 25 collaborators of Mark S. Diamond. A scholar is included among the top collaborators of Mark S. Diamond based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mark S. Diamond. Mark S. Diamond is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

13 of 13 papers shown
1.
Grohar, Patrick J., Karla V. Ballman, Leo Mascarenhas, et al.. (2024). SARC037: Phase II results of trabectedin given as a 1-hour (h) infusion in combination with low dose irinotecan in patients (pts) with relapsed/refractory Ewing sarcoma (ES).. Journal of Clinical Oncology. 42(16_suppl). 11508–11508. 5 indexed citations
2.
Dumbrava, Ecaterina E., Fábio M. Iwamoto, Mark Agulnik, et al.. (2024). Abstract CT066: Phase 1 study of MDM2 antagonist ASTX295 in patients with solid tumors with wild-type TP53. Cancer Research. 84(7_Supplement). CT066–CT066. 1 indexed citations
3.
Kim, Il‐Kyu, Mark S. Diamond, Salina Yuan, et al.. (2024). Plasticity-induced repression of Irf6 underlies acquired resistance to cancer immunotherapy in pancreatic ductal adenocarcinoma. Nature Communications. 15(1). 1532–1532. 20 indexed citations
4.
Tine, Brian Andrew Van, Jingqin Luo, Angela C. Hirbe, et al.. (2023). Randomized phase II trial of cabozantinib combined with PD-1 and CTLA-4 inhibition versus cabozantinib in metastatic soft tissue sarcoma.. Journal of Clinical Oncology. 41(17_suppl). LBA11504–LBA11504. 8 indexed citations
5.
Diamond, Mark S., Jeffrey Lin, & Robert H. Vonderheide. (2021). Site-Dependent Immune Escape Due to Impaired Dendritic Cell Cross-Priming. Cancer Immunology Research. 9(8). 877–890. 22 indexed citations
6.
Reddy, Vishruth K., Varsha Jain, Lee Hartner, et al.. (2021). Adult Pleomorphic Rhabdomyosarcomas: Assessing Outcomes Associated with Radiotherapy and Chemotherapy Use in the National Cancer Database. Sarcoma. 2021. 1–11. 1 indexed citations
7.
Morrison, Alexander H., Mark S. Diamond, Ceire Hay, Katelyn T. Byrne, & Robert H. Vonderheide. (2020). Sufficiency of CD40 activation and immune checkpoint blockade for T cell priming and tumor immunity. Proceedings of the National Academy of Sciences. 117(14). 8022–8031. 93 indexed citations
8.
Evans, Rebecca A., Mark S. Diamond, Andrew J. Rech, et al.. (2016). Lack of immunoediting in murine pancreatic cancer reversed with neoantigen. JCI Insight. 1(14). 123 indexed citations
9.
Diamond, Mark S., Michelle Kinder, Hirokazu Matsushita, et al.. (2011). Type I interferon is selectively required by dendritic cells for immune rejection of tumors. The Journal of Experimental Medicine. 208(10). 1989–2003. 864 indexed citations breakdown →
10.
Hildner, Kai, Brian T. Edelson, Whitney E. Purtha, et al.. (2008). Batf3 Deficiency Reveals a Critical Role for CD8α + Dendritic Cells in Cytotoxic T Cell Immunity. Science. 322(5904). 1097–1100. 1543 indexed citations breakdown →
11.
Sheehan, Kathleen C. F., Koon Siew Lai, Gavin P. Dunn, et al.. (2006). Blocking Monoclonal Antibodies Specific for Mouse IFN- α / β Receptor Subunit 1 (IFNAR-1) from Mice Immunized by In Vivo Hydrodynamic Transfection. Journal of Interferon & Cytokine Research. 26(11). 804–819. 206 indexed citations
12.
Dunn, Gavin P., Hiroaki Ikeda, Allen T. Bruce, et al.. (2005). Interferon-γ and Cancer Immunoediting. Immunologic Research. 32(1-3). 231–246. 118 indexed citations
13.
Dunn, Gavin P., Allen T. Bruce, Kathleen C. F. Sheehan, et al.. (2005). A critical function for type I interferons in cancer immunoediting. Nature Immunology. 6(7). 722–729. 481 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Helen Sabzevari Breakdown of academic impact, for papers by Surojit Sarkar Breakdown of academic impact, for papers by Daniel T. Utzschneider Breakdown of academic impact, for papers by Mercedes B. Fuertes Breakdown of academic impact, for papers by Shahram Salek‐Ardakani Breakdown of academic impact, for papers by Laura M. McLane Breakdown of academic impact, for papers by Silvia A. Fuertes Marraco Breakdown of academic impact, for papers by Shawn D. Blackburn Breakdown of academic impact, for papers by Christine Sedlik Breakdown of academic impact, for papers by Kristen J. Radford
Rankless by CCL
2026